Advanced biologic therapies and cardiovascular events in patients with inflammatory bowel disease
ABT were associated with significantly fewer ASCVD events than NABT in the IBD patient population. Among drug subclasses, interleukin 12/23 inhibitors were associated with the strongest benefit. Future prospective, randomized studies examining the efficacy and safety as well as the differential benefit of drug subclasses on ASCVD outcomes and mechanisms responsible for the ABT benefit are needed.
Authors
- Lara Chaaban (ORCID: https://orcid.org/0000-0003-1294-8790)
- Tarek Harb (ORCID: https://orcid.org/0000-0002-2573-5260)
- Gary Gerstenblith (ORCID: https://orcid.org/0000-0001-6046-6812)
- Joanna Melia (ORCID: https://orcid.org/0000-0002-0984-4600)
- Thorsten M. Leucker (ORCID: https://orcid.org/0000-0003-2569-6617)
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
Publication Details
- Journal
- American Journal of Preventive Cardiology
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1016/j.ajpc.2025.100991
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82